Adeno-associated virus (AAV) vectors are frequently used as donor templates for genome editing by homologous recombination. Although modification rates are typically under 1%, they are greatly enhanced by targeted double-stranded DNA breaks (DSBs). A recent report described clade F AAVs mediating high-efficiency homologous recombination-based editing in the absence of DSBs. The clade F vectors included AAV9 and a series isolated from human hematopoietic stem/progenitor cells (HSPCs). We evaluated these vectors by packaging homology donors into AAV9 and an AAVHSC capsid and examining their ability to insert GFP at the CCR5 or AAVS1 loci in human HSPCs and cell lines. As a control we used AAV6, which effectively edits HSPCs, but only when combined with a targeted DSB. Each AAV vector promoted GFP insertion in the presence of matched CCR5 or AAVS1 zinc finger nucleases (ZFNs), but none supported detectable editing in the absence of the nucleases. Rates of editing with ZFNs correlated with transduction efficiencies for each vector, implying no differences in the ability of donor sequences delivered by the different vectors to direct genome editing. Our results therefore do not support that clade F AAVs can perform high efficiency genome editing in the absence of a DSB.
Introduction
Interest in the use of genome editing technologies to correct human genetic mutations or precisely insert therapeutic gene cassettes at defined loci has greatly increased in recent years. 1 In the most common approach, targeted nucleases such as CRISPR/Cas9, zinc finger nucleases (ZFNs) or transcription activator-like effector nucleases (TALENs) generate doublestranded DNA breaks (DSB) at a specific sequence in the genome with high precision. [2] [3] [4] The subsequent repair of DSBs can result in insertions and deletions (indels) from the activity of the non-homologous end joining (NHEJ) DNA repair pathway, and this can be leveraged to disrupt an open reading frame or genetic element. 5, 6 In contrast, by also introducing a DNA donor template that is homologous to the chromosomal DNA surrounding the DSB, it is possible to harness homology-directed repair (HDR) pathways and thereby engineer specific DNA changes into the host genome. 7 DNA homology donors can be provided by plasmids, oligonucleotides or viral genomes. 4, 5, [8] [9] [10] Among these, adeno-associated viral (AAV) vectors have emerged as particularly effective vehicles for delivery of DNA homology donors. 5, [11] [12] [13] AAV is a small parvovirus encapsidating a single-stranded DNA genome of about 4.7 kb. 14 Recombinant AAV vector genomes contain only the viral inverted terminal repeats (ITRs) and persist as stable episomal DNA, with expression detected for over a decade in vivo. [15] [16] [17] [18] In addition, many different AAV serotypes are available, comprising both natural and engineered capsids, that allow transduction of a wide variety of cell types and tissues in vitro and in vivo. [19] [20] [21] [22] Accordingly, AAV vectors are being evaluated as gene delivery vectors in a number of human clinical trials. 22, 23 AAV vectors have a long history of use as homology donors in genome targeting applications. Such studies over the past 20 years have typically reported gene insertion rates below 1% in the absence of a targeted nuclease. [24] [25] [26] [27] In contrast, combining AAV donors with targeted nucleases has led to high rates of genome editing, most notably in hematopoietic cells, where combining AAV serotype 6 donors with ZFNs, 5, 11 TALENs, 13 or CRISPR/Cas9 12, 28 has resulted in gene editing rates of 15-60% in T cells, B cells and CD34 + hematopoietic stem and progenitor cells (HSPCs). Nuclease-mediated engineering is accompanied by potential risks from off-target DNA breaks, although improvements in nuclease engineering [29] [30] [31] [32] and enhanced off-target detection methods [33] [34] [35] are reducing these concerns. At the same time, editing technologies that do not require DSBs are also being developed, such as those that exploit base editing [36] [37] [38] and potentially transposon integration. 39 Recently, Smith et al. 40 reported that the use of AAV vectors generated with capsids from clade F viruses could mediate highly efficient HDR in the absence of targeted DNA breaks.
Clade F includes serotype AAV9, as well as a closely related family of novel capsids termed
AAVHSCs that were previously isolated by their group from human HSPCs. 41 These clade F AAV capsids were reported to mediate stable gene insertion in both cell lines and primary human HSPCs, resulting in scarless modifications that are consistent with HDR in upwards of 50% of HSPCs at the AAVS1 locus and 8% of HSPCs at two sites in the IL2RG gene. Such an effect was not seen with identical AAV genomes packaged into capsids from other serotypes.
The authors further reported that this genome editing required BRCA2, suggesting dependence on homologous recombination, although a more thorough explanation of the underlying mechanism was not obtained. Given the departure of these findings from previous studies of nuclease-free genome editing using AAV vectors, we were interested to evaluate the utility of clade F AAV vectors in genome editing, both with and without matched targeted nucleases.
Results

Transduction of human HSPCs and cell lines by AAV6 and clade F vectors
Smith et al. reported that AAV genomes packaged into clade F capsids could direct high levels of homologous recombination-based genome editing in the absence of a catalyzing DSB. 40 The authors further suggested that the concentration of AAV genomic DNA within the nucleus may have played a role in this process, since they reported significantly better transduction and nuclear entry rates in human CD34 + HSPCs when using clade F AAVs compared to other serotypes, including AAV6, and that the efficiency of transduction correlated with the editing frequencies obtained. These results were somewhat surprising, given that we and others have previously reported that AAV6 vectors more efficiently transduce HSPCs than the prototype clade F vector, AAV9. 5, 42 We therefore directly compared the ability of AAV6 and AAV9 vectors to transduce both HSPCs and three different cell lines. Using an AAV genome carrying only a CMV-GFP cassette and no homology arms, we observed transduction rates of HSPCs after 2 days that ranged from ~20-80% when using AAV6 at multiplicities of infection (MOIs) between 10 3 and 10 5 . In contrast, the matched AAV9 vectors transduced less than 3% of cells at the highest MOI of 10 5 (Fig. 1A) . Similarly, we found that AAV6 vectors transduced all three cell lines better than the AAV9 vectors ( 
AAV vectors mediate efficient homology-directed gene insertion in K562 cells only in the presence of a targeted nuclease
To further investigate targeted integration by clade F AAVs we generated a mutant capsid, AAV9-G505R. This vector matches the reported amino acid sequence of AAVHSC13 and AAVHSC17 and contains a point mutation (G505R) that is conserved among 6 of the 17 6 AAVHSC serotypes described. 41 We produced AAV6, AAV9 and AAV9-G505R vectors packaging a genome comprising a PGK-GFP cassette flanked by CCR5 homology arms ( Fig.   2A ), with which we have previously evaluated nuclease-driven HDR-mediated gene editing in HSPCs. 5 K562 cells transduced with AAV6, AAV9, or AAV9-G505R vectors were 48.0%, 8.81%, and 4.38% GFP + respectively after 2 days, indicating that all three vectors were able to transduce these cells at varying efficiencies ( Fig. 2B ). After 14 days, all cell populations were <0.5% GFP + suggesting that the vast majority of the initial GFP expression at day 2 originated from episomal AAV genomes and that minimal, if any, integration of the transgene cassette had occurred ( Fig. 2B -C). In contrast, when the cells were also electroporated with mRNA coding for CCR5-specific ZFNs, stable GFP expression was detected after 14 days at frequencies that were similar to the day 2 transduction values ( Fig 2B-C) . Site-specific insertion of the GFP cassette at the CCR5 locus was confirmed using an in-out PCR assay 5 which only produced a signal in the ZFN-treated samples ( Fig. 2D ). Together, these observations indicate that although each of the three AAV vectors could deliver homology donors that promote HDR-mediated gene addition in the presence of a targeted DNA break, they were unable to do so efficiently in the absence of such a DSB.
Since the transduction rates at day 2 seemed to be predictive of the genome editing rates achieved in the presence of the ZFNs, we performed AAV vector genome copy number analysis at day 2 by ddPCR. The number of cell-associated AAV genomes at day 2 strongly correlated with the frequency of GFP + cells at day 14 (r 2 > 0.999) for all 3 serotypes when codelivered with the ZFN mRNA ( Fig. 2E ). These data suggest that transduction efficiency rather than any intrinsic properties of the different AAV serotypes governs the rate of nucleasedependent gene addition.
To verify that the lack of nuclease-independent genome editing we observed for AAV6 and the two clade F vectors was not specific to the CCR5 locus, we generated AAV6, AAV9, and AAV9-G505R vectors with genomes that targeted the AAVS1 locus. To mimic the strategy used by Smith et al., the vector genomes comprised a promoter-less GFP cassette whose expression relied on an upstream splice acceptor and T2A sequence, and containing AAVS1 homology arms (AAVS1-SA-2A-GFP) ( Fig. 3A ). 40 Since this construct lacks an internal promoter, GFP expression should only be observed following insertion into the host genome downstream of a promoter and within an intron and, as expected, episomal expression was not detected at day 2 in any of the samples transduced with AAV only (Fig 3B) . At day 14, GFP expression ( Fig. 3B -C) and site-specific insertion ( Fig. 3D ) in K562 cells was only observable above background levels in cells also treated with AAVS1-specific ZFN mRNA, with frequencies that were comparable to those observed at CCR5. Vector copy number at day 2 also strongly correlated with GFP expression at day 14 in the presence of ZFNs, also confirming the importance of transduction efficiency in determining the rates of nuclease-dependent gene editing at this locus ( Fig. 3E ).
Efficient transduction does not support nuclease-independent genome editing by clade F
AAVs in HEK-293T cells
A potential limitation of our analyses in K562 cells is the relatively inefficient transduction (<10%) we observed with clade F AAVs. To address this concern, we next tested the panel of vectors in HEK-293T cells, which were more permissive to AAV9 transduction in our hands ( Fig.   1B ). Using a higher MOI of 5 x 10 5 of the CCR5-PGK-GFP vectors, we observed GFP expression at day 2 in 97.5% of cells with AAV6, 55.9% with AAV9, and 19.8% with AAV9-G505R ( Fig. 4A ). Despite these high initial rates of AAV transduction, GFP expression declined significantly in all populations by day 17, mirroring the drop we previously observed using AAV vectors lacking homology arms (Fig. 1C) , and again suggesting that the GFP expression cassette had not been incorporated into the genome. Similarly, cells transduced with equivalent MOIs of AAV vectors packaging the AAVS1-SA-2A-GFP genome did not exhibit GFP expression above background at either day 2 or day 17, providing further evidence that site-specific gene editing had not occurred ( Fig. 4B ). Together, these results suggest that neither AAV6, AAV9, nor AAV9-G505R vectors can mediate efficient genome editing in the absence of a targeted nuclease, even when high levels of vector transduction have occurred.
Lack of homology-directed gene insertion in HSPCs by AAV vectors in the absence of a matched targeted nuclease
Finally, we investigated the editing efficiency of AAV homology donors in primary human HSPCs. In agreement with our data obtained using the CMV-GFP reporter vectors ( Fig. 1A) , GFP levels at day 2 post-transduction for CCR5-PGK-GFP constructs were much more efficient when packaged in AAV6 capsids than either AAV9 or AAV9-G505R ( Fig. 5A ). Indeed, the clade F vectors only produced 0.54% and 0.32% GFP + cells, respectively, for AAV9 and AAV9-G505R when using an MOI of 5 x 10 4 . This MOI is comparable to that employed by Smith et al. in HSPCs. 40 By day 10, GFP expression from all of the cells receiving AAV vectors alone had fallen to below 0.3% GFP + (Fig. 5B-C) . In contrast, combining the vectors with CCR5-specific ZFNs promoted stable GFP expression at day 10 that was above the frequencies observed for the vector only controls ( Fig. 5B-C) . The levels obtained with the two clade F vectors were <1%, but this likely reflected their poor ability to transduce HSPCs, which would limit genome editing rates. Finally, we also evaluated stable GFP expression levels when AAVS1-specific ZFNs were combined with the CCR5 homology donor vectors ( Fig. 5B-C ). This mismatched nuclease will introduce a DSB at a non-homologous locus, which can lead to low levels of NHEJ-mediated end capture of AAV genomes, 5 and indeed we observed a slight enhancement of GFP expression for the AAV6 vectors above the background levels with no ZFN.
We repeated these analyses using vectors containing the AAVS1-SA-2A-GFP homology donor genome, delivered alone to HSPCs or in combination with matched (AAVS1) or mismatched (CCR5) ZFNs ( Fig. 5D -E). The results mirrored those seen at the CCR5 locus, since GFP expression above background was only detected in cells also receiving the AAVS1-1 0 AAV vectors are also used in more conventional gene therapy approaches and are accruing a record of safety in human clinical trials. Random integration into the host genome reportedly occurs at extremely low frequencies (<0.1%) and appears to exhibit no deleterious preferences in targeting. 45 Some studies have suggested a link between AAV delivery and hepatocellular carcinoma in mice, though others did not reproduce these findings in nonhuman primates and patients. [46] [47] [48] To date, no reports have indicated germline modification. However, in the absence of a targeted DSB, the ability of AAV vectors to specifically modify the human genome has been much more limited, making therapeutic applications of AAV mediated HDR more challenging and potentially dependent on in vivo selection or expansion. 25, 26, 49 To achieve targeted integration in vivo, clinical trials are now progressing using AAV vectors to deliver both genome editing components and the donor DNA for MPS I (NCT02702115), MPS II, (NCT03041324) and hemophilia B (NCT02695160), though the mechanism of gene insertion can include both HDR and site-specific NHEJ-mediated insertion of the AAV transgene. 50, 51 However, the requirement for both a nuclease and a donor template complicates this in vivo delivery platform. Hence, the report of efficient homologous recombination by clade F AAV vectors in the absence of targeted nucleases is a potentially exciting discovery. 40 To evaluate this reported ability of clade F vectors, we packaged homology templates for the CCR5 or AAVS1 loci into AAV9 vectors, or those containing an additional point mutation G505R, which corresponds to the reported variants AAVHSC13 and AAVHSC17. 41 As a control, we also included AAV6 vectors. The AAVS1 homology donor genome we designed mimicked the approach used by Smith et al., 40 where a promoter-less GFP reporter was placed downstream of a splice acceptor cassette, so that site-specific integration into the PPP1R12C intron could result in GFP expression. In contrast, the CCR5 homology construct contained an internal PGK promoter, expected to drive GFP expression from both episomal and integrated forms of the vector genome. We confirmed that both donor templates were HDR-competent by demonstrating stable GFP expression in the presence of a matched ZFN and further confirmed 1 1 that integration had occurred into the targeted loci using a specific in-out PCR. However, in the absence of the matched nucleases, we observed only background levels of GFP expression and no detectable PCR products when all 6 of the vectors were tested in human HSPC and two different cell lines.
A possible explanation proposed for the properties of the clade F vectors described by Smith et al. was enhanced delivery to the nuclei of target cells. Although we did not detect nuclease-independent editing, we consistently observed a strong correlation between the AAV transduction rates we measured on day 2 and the genome editing frequency we measured at later time points in the presence of matched ZFNs. This observation was particularly compelling in K562 cells, where the number of cell-associated AAV genomes nearly perfectly correlated with the rate of stable GFP insertion that was achieved across the three capsids. Similarly, the GFP transduction pattern we observed in HSPCs at day 2 matched the relative nucleasemediated editing rates that persisted at day 10 (AAV6 >>> AAV9 > AAV9-G505R). Together, these data suggest that our clade F vectors did not display a unique propensity for HDR; instead, the concentration of homology donor template delivered to the cell was the major determinant of editing rates for all three AAV serotypes tested.
Other aspects of our work did not agree with the results reported by Smith et al., and it is possible that these could account for the large discrepancies we observed in nuclease-free editing capabilities. For example, the relative tropism we obtained with AAV6 and AAV9 vectors on HSPCs is in stark contrast to their observations. In HSPCs and in cell lines, we observed superior transduction using AAV6 over either of the clade F vectors we tested at equivalent MOIs, which aligns with previously published comparisons of AAV6 and AAV9 tropism in HSPCs from both our group and others. 5, 42 Indeed, AAV6 is now routinely used by many different labs to transduce HSPCs for genome editing applications. 12, 13, 52 Our observations are also consistent with reports that have described overall low transduction in vitro with AAV9. 20, 21 In contrast, Smith et al. report 27-fold higher nuclear entry in HSPCs for a pool of clade F 1 2 vectors compared to AAV6, whereas we observed roughly the inverse in K562 cells-i.e. an average of 36-and 48-fold higher VCNs with AAV6 compared to AAV9 and AAV9-G505R, respectively. 40 It is also possible that the published capsid sequence for AAVHSC13 and AAVHSC17 41 is not sufficient to reproduce these results. These variants differ from AAV9 by a single G505R mutation in VP3, although AAVHSC17 was also reported to contain a silent mutation in VP1. 41 Confusingly, both transduction experiments and genome editing results in the recent Smith et al.
report give differing efficiencies for AAVHSC13 and AAVHSC17. 40 It is unclear why these two capsids would behave differently, unless the silent mutation in AAVHSC17 has some unusual regulatory function, such as altering the traditional 1:1:10 VP1:VP2:VP3 ratio of AAV capsid proteins. Nevertheless, these potential subtleties of AAVHSC capsids do not explain the different results obtained with the prototype clade F member AAV9, which is a well-studied serotype that is used in many applications.
Although we cannot explain these observed in vitro tropism differences, we recognized that the lower transduction efficiencies we obtained when using clade F vectors compared to AAV6 were a confounding factor. We achieved less than 10% GFP + cells in K562 cells and less than 1% GFP + cells in HSPCs, even when using an MOI that was 16-fold higher than we typically need to achieve HDR insertion rates in HSPCs at the CCR5 locus of 15-50% (5 x 10 4 vs. 3 x 10 3 ) (unpublished observations). 5 While it is possible that our transduction levels were too low to detect nuclease-free HDR editing in the assays we used, the MOIs we used were within the range used by Smith et al, 40 although the well-documented potential variability of AAV titers between labs must be considered when making these sorts of comparisons. 53, 54 Additionally, the vector copy numbers we found in K562 cells were at least as high as those reported by Smith in HSPCs, albeit with the opposite observations of relative efficiency between AAV6 and the clade F AAVs. These data suggest that we are using a similar range of AAV doses.
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Nevertheless, to try to rule out such a dose effect, we repeated the analyses in HEK-293T cells, where we could achieve transduction rates of >50% of cells with AAV9 vectors, and >20% with AAV9-G505R. These transduction frequencies are in line with those reported by Smith et al. to yield gene insertion rates in excess of 10%, depending on the specific clade F serotype used. However even with this high level of transduction in HEK-293T cells, we found no evidence of efficient site-specific genome editing in the absence of a targeted nuclease with AAV9 or AAV9-G505R vectors. Possibly, higher MOIs may be needed to replicate this phenomenon, although it may then become challenging to make AAV preparations of sufficient volume and concentration to achieve such higher MOIs. Moreover, in vivo delivery of high doses of AAV has been reported to lead to acute toxicity. 55 In summary, our findings suggest that, like AAV6, clade F AAVs are unable to mediate high-frequency HDR in the absence of a targeted DNA break. We observed this at 2 different loci in 3 distinct cell types, including primary human HSPCs. While our data agrees that delivery of the donor DNA template is a critical determinant of the rate of genome editing, inclusion of a matched targeted nuclease was required for any detectable site-specific gene insertion. The gene insertion rates we report without ZFNs align with the consensus in the field that AAV vectors typically achieve less than 1% gene insertion in the absence of a catalytic DNA break. [24] [25] [26] At present we are unable to explain our inability to reproduce the findings of Smith et al. 40 Perhaps there are unidentified features in their AAV constructs, or some aspect of their vector production, purification, or titration methods that contributed to this phenomenon. Nevertheless, the reported ability of clade F AAVs to perform highly efficient nuclease-independent genome editing by homologous recombination is clearly not a universal phenomenon.
Materials & Methods
AAV plasmids
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The AAV6 capsid plasmid pRC6 was purchased from Cell BioLabs (San Diego, CA).
AAV9 capsid plasmid p5E18-VD2/9 was obtained from the University of Pennsylvania Vector Core. AAV9-G505R was generated by PCR mutagenesis of p5E18-VD2/9 using the In-Fusion Cloning HD Plus System (Takara Bio, Mountain View, CA). The pITR-CCR5-PGK-GFP vector genome plasmid contains AAV2 ITRs, CCR5 homology arms of 473 bp (left) and 1431 bp (right), a hPGK promoter, eGFP, and a BGH polyA signal has been previously described. 5 Plasmid pITR-AAVS1 contains homology arms of 801 bp (left), and 568 bp (right), 5 
AAV vectors
AAV6 and AAV9 vectors expressing CMV-GFP were purchased from Vigene Biosciences (Rockville, MD). AAV6-CCR5-PGK-GFP was produced at Sangamo Therapeutics as previously described. 5 All other AAV vectors were produced in-house using the AAV helper free packaging system (Cell Biolabs). Briefly, one day before transfection, 9 x 10 6 293AAV cells (Cell Biolabs) were seeded in 15 cm diameter dishes to achieve 70-80% confluence on the day of transfection. Cells were co-transfected with the following three plasmids: pHelper; capsid plasmid pAAV-RC6 for AAV6, p5E18-VD2/9 for AAV9, or p5E18-VD2/9-G505R for AAV9-G505R; and pITR-CCR5-PGK-GFP or pITR-AAVS1-SA-2A-GFP. A total of 81 µg of plasmids were transfected by calcium phosphate transfection method at a 1:1:1 ratio. Sixteen hours after transfection, cells were washed once with PBS and kept in fresh DMEM supplemented with 10% FBS.
For AAV9 and AAV9-G505R production, cell pellets were harvested at 72 hours posttransfection and freeze/thawed at least once with a -80°C/37°C cycle. The cell pellets were then lysed (150mM NaCl, 20mM Tris pH8, 0.5% sodium deoxycholate, and 100 U/mL benzonase) for 1 5 2 hours. Cell debris were removed by centrifugation at 3000 g for 15 mins. The crude lysate was subjected to iodixanol gradient ultracentrifugation at 59000 rpm for 70 minutes. After ultracentrifugation, the 40% iodixanol fraction containing AAV vectors was isolated, and further concentrated and buffer exchanged to D-sorbitol containing PBS (PBS with 5% D-sorbitol and 350mM NaCl) by centrifugation through an Amicon Ultra-50 centrifugal filter (Millipore, Burlington, MA) according to the manufacturer's instructions. The concentrated vectors were stored at -80°C until use.
For AAV6 production, culture medium was harvested at 72 hours post-transfection and filtered through a 0.22 µM filter. The filtered medium was then concentrated 20-fold by tangential flow filtration (TFF) system (Spectrum Laboratories, Rancho Dominguez, CA), using a polyethersulfone membrane hollow fiber unit with 100 kDa molecular weight cut off and 155 cm 2 filtration surface. The KR2i peristaltic pump was used to pump the medium through the filter.
The concentrated medium was then subjected to iodixanol gradient ultracentrifugation as described above.
AAV vector titration
To remove residual plasmid DNA, AAV vectors were treated with DNaseI (New England Biolabs, Ipswich, MA) at 37°C for 30 mins, followed by heat inactivation at 75°C for 10 mins. 
ZFN reagents and mRNA production
ZFNs targeting the CCR5 and AAVS1 loci have been described previously. 5 
Vector copy number analysis
Cells were pelleted by centrifugation and DNA was isolated using the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany). Roughly 5 ng of genomic DNA was mixed with primers and probes for a human RPP30 copy number assay labeled with HEX (Bio-Rad, Hercules, CA) 1 8
as an internal control, and GFP-specific primers and probe were as follows: Forward 5'-AGCAAAGACCCCAACGAGAA-3', Reverse 5'-GGCGGCGGTCACGAA-3', Probe 5'-FAM-CGCGATCACATGGTCCTGCTGG-3'. Droplets were prepared using ddPCR Supermix for Probes (No dUTP) and a QX200 Droplet Generator (Bio-Rad). The PCR reaction was run on a C1000 Touch Thermal Cycler with the following conditions: 95 °C 10 min, 40 cycles (94° C 30 s, 60° C 1 min), 98° C 10 min, and 4° C forever. After the PCR reaction, the samples were read on a QX200 Droplet Reader and the data were analyzed with QuantaSoft analysis software (Bio-Rad). Linear regression analysis was performed using GraphPad Prism software (San Diego, CA). 
In-out PCR
